Global Human Plasma-derived Hyperimmune Product Market Growth 2025-2031
Description
The global Human Plasma-derived Hyperimmune Product market size is predicted to grow from US$ 2163 million in 2025 to US$ 3134 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
LP Information, Inc. (LPI) ' newest research report, the “Human Plasma-derived Hyperimmune Product Industry Forecast” looks at past sales and reviews total world Human Plasma-derived Hyperimmune Product sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Plasma-derived Hyperimmune Product sales for 2025 through 2031. With Human Plasma-derived Hyperimmune Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Plasma-derived Hyperimmune Product industry.
This Insight Report provides a comprehensive analysis of the global Human Plasma-derived Hyperimmune Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Plasma-derived Hyperimmune Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Plasma-derived Hyperimmune Product market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Plasma-derived Hyperimmune Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Plasma-derived Hyperimmune Product.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Plasma-derived Hyperimmune Product market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Plasma-derived Hyperimmune Product market?
What factors are driving Human Plasma-derived Hyperimmune Product market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Plasma-derived Hyperimmune Product market opportunities vary by end market size?
How does Human Plasma-derived Hyperimmune Product break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
LP Information, Inc. (LPI) ' newest research report, the “Human Plasma-derived Hyperimmune Product Industry Forecast” looks at past sales and reviews total world Human Plasma-derived Hyperimmune Product sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Plasma-derived Hyperimmune Product sales for 2025 through 2031. With Human Plasma-derived Hyperimmune Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Plasma-derived Hyperimmune Product industry.
This Insight Report provides a comprehensive analysis of the global Human Plasma-derived Hyperimmune Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Plasma-derived Hyperimmune Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Plasma-derived Hyperimmune Product market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Plasma-derived Hyperimmune Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Plasma-derived Hyperimmune Product.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Plasma-derived Hyperimmune Product market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Plasma-derived Hyperimmune Product market?
What factors are driving Human Plasma-derived Hyperimmune Product market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Plasma-derived Hyperimmune Product market opportunities vary by end market size?
How does Human Plasma-derived Hyperimmune Product break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
118 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Human Plasma-derived Hyperimmune Product by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Human Plasma-derived Hyperimmune Product by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
